Follow-Up of Patients Who Achieved Sustained Virologic Response After Interferon-Free Treatment Against Hepatitis C Virus: Focus on Older Patients

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2021 Aug 27

PMID 34440967

Citations 4

Authors

Kazushige Nirei

Tatsuo Kanda

Ryota Masuzaki

Taku Mizutani

Mitsuhiko Moriyama

Affiliations

Soon will be listed here.

Abstract

: Direct-acting antiviral agents (DAAs) have improved sustained virologic response (SVR) rates in patients with chronic hepatitis C virus (HCV) infection. Our aim was to elucidate the occurrence of hepatocellular carcinoma (HCC) and to compare the outcomes of patients aged 75 years or older (older group) with those of patients younger than 75 years (younger group) after SVR. : Among 441 patients treated with interferon-free DAA combinations, a total of 409 SVR patients were analyzed. We compared the two age groups in terms of HCC incidence and mortality rates. : Older and younger groups consisted of 68 and 341 patients, respectively. Occurrence of HCC after SVR did not differ between the two groups of patients with a history of HCC. Occurrence of HCC after SVR was observed more in younger patients without a history of HCC ( < 0.01). Although older patients without a history of HCC had a higher mortality rate ( < 0.01), their causes of death were not associated with liver diseases. Among younger patients without a history of HCC, none died. : After SVR, liver disease may not be a prognostic factor in older HCV patients without a history of HCC.

Citing Articles

Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response.

Ishido S, Tamaki N, Kurosaki M, Mori N, Tsuji K, Hasebe C JGH Open. 2023; 7(6):424-430.

PMID: 37359109 PMC: 10290273. DOI: 10.1002/jgh3.12914.

COVID-19 After Treatment With Direct-acting Antivirals for HCV Infection and Decompensated Cirrhosis: A Case Report.

Ikegami C, Kanda T, Ishii T, Honda M, Yamana Y, Tanaka R In Vivo. 2022; 36(4):1986-1993.

PMID: 35738621 PMC: 9301408. DOI: 10.21873/invivo.12923.

Left Gastric Vein Width Is an Important Risk Factor for Exacerbation of Esophageal Varices Post Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices in Cirrhotic Patients.

Mizutani T, Nirei K, Kanda T, Honda M, Ishii T, Arima S Medicina (Kaunas). 2022; 58(2).

PMID: 35208529 PMC: 8875323. DOI: 10.3390/medicina58020205.

Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan.

Yamana Y, Kanda T, Matsumoto N, Honda M, Kumagawa M, Sasaki R J Clin Med. 2021; 10(23).

PMID: 34884231 PMC: 8658140. DOI: 10.3390/jcm10235529.

References

Cheung M, Walker A, Hudson B, Verma S, McLauchlan J, Mutimer D . Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016; 65(4):741-747. DOI: 10.1016/j.jhep.2016.06.019. View

Afdhal N, Reddy K, Nelson D, Lawitz E, Gordon S, Schiff E . Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370(16):1483-93. DOI: 10.1056/NEJMoa1316366. View

Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C . Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019; 393(10179):1453-1464. DOI: 10.1016/S0140-6736(18)32111-1. View

Li D, Ren Y, Fierer D, Rutledge S, Shaikh O, Lo Re 3rd V . The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology. 2017; 67(6):2244-2253. DOI: 10.1002/hep.29707. View

Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F . Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014; 21(11):762-8. DOI: 10.1111/jvh.12312. View

Ouchi Y, Rakugi H, Arai H, Akishita M, Ito H, Toba K . Redefining the elderly as aged 75 years and older: Proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. Geriatr Gerontol Int. 2017; 17(7):1045-1047. DOI: 10.1111/ggi.13118. View

Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V . FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46(1):32-6. DOI: 10.1002/hep.21669. View

Kanda T, Lau G, Wei L, Moriyama M, Yu M, Chuang W . APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?. Hepatol Int. 2018; 13(2):103-109. PMC: 6418053. DOI: 10.1007/s12072-018-9915-5. View

Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T . Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017; 67(5):933-939. DOI: 10.1016/j.jhep.2017.05.028. View

10.

Virlogeux V, Pradat P, Hartig-Lavie K, Bailly F, Maynard M, Ouziel G . Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. Liver Int. 2017; 37(8):1122-1127. DOI: 10.1111/liv.13456. View

11.

Kaneko T, Kanda T, Nirei K, Matsumoto N, Yamazaki M, Shibata T . Follow-up Results of GT2 Patients After Sofosbuvir/Ribavirin Therapy: Careful Attention to Occurrence of HCC. Anticancer Res. 2019; 39(7):3855-3862. DOI: 10.21873/anticanres.13535. View

12.

Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Haga Y . Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. Int J Med Sci. 2016; 13(6):418-23. PMC: 4893555. DOI: 10.7150/ijms.15519. View

13.

Tsuji K, Kurosaki M, Itakura J, Mori N, Takaki S, Hasebe C . Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol. 2018; 53(10):1142-1150. DOI: 10.1007/s00535-018-1455-1. View

14.

Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M . Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010; 52(2):518-27. DOI: 10.1002/hep.23691. View

15.

Mizokami M, Dvory-Sobol H, Izumi N, Nishiguchi S, Doehle B, Svarovskaia E . Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies. J Viral Hepat. 2016; 23(10):780-8. DOI: 10.1111/jvh.12549. View

16.

Backus L, Belperio P, Shahoumian T, Mole L . Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. Hepatology. 2017; 69(2):487-497. DOI: 10.1002/hep.29408. View

17.

Kanwal F, Kramer J, Asch S, Chayanupatkul M, Cao Y, El-Serag H . Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017; 153(4):996-1005.e1. DOI: 10.1053/j.gastro.2017.06.012. View

18.

Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, Persico M . Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Dig Liver Dis. 2018; 51(2):310-317. DOI: 10.1016/j.dld.2018.10.014. View

19.

Nirei K, Nakamura H, Matsuoka S, Yamana Y, Yoda S, Hirayama A . Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection. Intern Med. 2017; 56(7):787-790. PMC: 5457921. DOI: 10.2169/internalmedicine.56.7948. View

20.

Yoshimasu Y, Furuichi Y, Kasai Y, Takeuchi H, Sugimoto K, Nakamura I . Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C. J Gastrointestin Liver Dis. 2019; 28(1):63-71. DOI: 10.15403/jgld.2014.1121.281.hpc. View